COVID-19 Vaccine Pipeline: Introduction

  • COVID-19 is an infectious disease caused by the coronavirus. COVID-19 began its outbreak in Wuhan, China in December 2019. The World Health Organization (WHO) declared COVID-19 as Public Health Emergency of International Concern on January 30, 2020.
  • COVID-19 is spreading rapidly across the globe and almost every country has reported notable number of cases as well as death due to this this infection
  • Till date, the U.S. has recorded highest number of COVID-19 cases with count of more than one million active cases and more than 60,000 deaths. In Europe, more than 1.4 million active cases of COVID-19 have been reported as of April 30, 2020 with Italy being the worst affected country in the region. Italy has reported around 200,000 Covid-19 cases and more than 27,000 deaths.
  • The most common symptoms associated with COVID-19 are fever, dry cough, tiredness, aches and pains, nasal congestion, sore throat; and diarrhea. In the beginning stages of the COVID-19 infections, the symptoms are very mild. According to the WHO, 1 out of every 5 COVID-19 patients becomes seriously ill and faces breathing problem.
  • No perfect treatment or cure is available to treat the disease till date and lots of research and development activities are being carried out by leading players operating in the biopharmaceutical market place and all are expecting some positive outcomes very soon
  • The WHO has facilitated and accelerated efforts on the development of COVID-19 vaccine on such a scale that was not ever seen before in history
  • Healthcare experts estimate that the fast tracked vaccine development process could take around 12 to 18 months to successfully reach the market

Are you a Start-up willing to make it big in the Business? Grab an Exclusive PDF Brochure of COVID-19 Vaccine Pipeline Market Report

COVID-19 Vaccine Pipeline: Clinical Trial Phase 2/3

  • The University of Melbourne and Murdoch Children’s Research Institute are testing Bacillus Calmette-Guerin (BCG) live-attenuated vaccine for COVID-19. According to a research article published in MedRxIV in April 2020, the people in countries with BCG vaccination program at childhood are less virulent to COVID-19 than that of people in countries without BCG vaccination program.
  • Researchers at Radboud University Medical Center (The Netherlands) have launched the phase-3 BCG-CORONA trial on March 31, 2020 and plan to enroll 1,500 healthcare workers to receive the BCG vaccine or placebo

Clinical Trial Phase 2

  • China-based biotech company Sinovac Biotech is developing COVID-19 vaccine candidate PiCoVacc. The company has claimed to have successfully tested the vaccine against COVID-19 in monkeys. The company is in talks with the World Health Organization to launch the phase-3 clinical trials in the region where the COVID-19 cases are rapidly spreading.
  • Massachusetts-based biotech company Moderna has developed the mRNA-1273 COVID-19 vaccine candidate. The mRNA-1273 is currently in phase-2 stage of clinical trial pipeline study and the USFDA has awarded the fast track designation for this candidate.
  • The China National Pharmaceutical Group (Sinopharm) is developing the inactivated vaccine candidate against COVID-19. The vaccine candidate has received the approval from the National Medical Products Administration and is currently in phase-2 of clinical trial pipeline studies.

Expanding Operations in Future? To Get the Perfect Launch Ask for a Custom COVID-19 Vaccine Pipeline Market Report

Clinical Trial Phase 1

  • China-based biotechnology company CanSino Biologics has used the adenovirus type 5 vector (Ad5) to develop novel COVID-19 vaccine. The preliminary safety data from phase-1 clinical trials is positive and it allowed the company to plan for phase-2 clinical trial studies.
  • The Oxford university’s Jenner Institute in collaboration with AstraZeneca is developing the ‘ChAdOx1 nCoV-19' coronavirus vaccine. The vaccine has shown the positive results on six rhesus macaque monkeys in March 2020. After the positive results from the initial trials on macaque monkey, the Oxford’s team is planning to test the vaccine on 6,000 people by the end of May 2020. If the clinical trials are successful in humans, then few million doses of the vaccine would be available by the end of September 2020.
  • The Serum Institute of India has planned to collaborate with Oxford University for the manufacture of vaccine if clinical trials are successful. The Serum Institute of India can produce 5 million doses of vaccine per month for the first 6 months and after that, the company can scale up to 10 million doses per month.
  • Inovio Pharmaceuticals is developing DNA vaccine INO-4800 against COVID-19.  The Inovio Pharmaceuticals and the International Vaccine Institute (IVI) in association with Korea National Institute of Health (KNIH) are conducting phase 1/2 clinical trials in Korea.
  • Pfizer Inc. and BioNTech have collaborated to develop COVID-19 vaccine candidate BNT 162.  The BNT-62 is currently under phase 1/2 clinical trial study. The human trials are also started with BNT 162 in the U.S.

Pre-clinical

  • A lot of companies are developing COVID-19 vaccine candidates in preclinical studies. Some of companies having vaccine candidates in preclinical studies are Novavax, CureVac, Generex Biotechnology, Vaxart, Medicago, Takis Biotech, Altimmune, and Johnson and Johnson.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Covid19 Vaccine Pipeline Market

Pre Book